安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- A Study of JNJ-64042056 in Participants With Preclinical . . . - Janssen
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo
- Home | Global Trial Finder
What is a Clinical Trial? A clinical trial, also called a research study, is a scientific evaluation that helps medical professionals learn about an investigational medication or vaccine
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of . . .
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML)
- Privacy Policy section - Janssen CarePath
Receiving program and educational communications from us: If you no longer want to receive Janssen CarePath Program Communications from us on a going-forward basis, please contact us via our Call Center at 877-CarePath (877-227-3728) Receiving marketing communications from us:
- A Phase 1 2 Study of Bleximenib in Participants With Acute Leukemia
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion) The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D
- A Study of JNJ-88549968 for the Treatment of Calreticulin . . . - Janssen
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion)
- A Study of Amivantamab Alone or in Addition to Other . . . - Janssen
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent metastatic head and neck cancer The study will also confirm the recommended Phase 2 combination dose (RP2CD) for
- A Study of Milvexian in Participants After an Acute Ischemic . . . - Janssen
Inclusion Criteria: * Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (NIHSS) score less than or equal to (=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic event
|
|
|